Horizon Pharma begins Actimmune’s Phase III trial for Friedreich's Ataxia

Ireland-based Horizon Pharma has started the Phase III study of Actimmune (interferon gamma-1b) to treat patients with Friedreich's Ataxia (FA), a degenerative neuro-muscular disorder.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news